The PAM50 test identifies a tumour’s biological subtype (Luminal A, Luminal B, HER2-enriched or Basal-like) and generates a risk of recurrence (ROR) score between 0 and 100, which stratifies patients into low-, intermediate- and high-risk groups accordingly. Here, ERBB2 is linked to neoplasm.